

Nature's Longevity Code: Evolutionary mRNA Therapeutics to Combat Fibrosis and Extend Healthspan Haim Belinson

: Company name caVos Biotechnology * Website <https://cavostx.com/> * CEO name Haim Belinson: Biotech/Pharma (Delete categories you are not selecting) Select one SESSION per abstract from the list below * (Delete sessions you are not selecting) “The Future of Aging: Where Longevity Meets Innovation.” You may delete the section instructions, leaving only the bolded bullet title Answers below should not exceed 60 words per question:

- **Executive Summary / Investment Rational:** Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths. caVos leverages comparative genomics to uncover longevity-linked antifibrotic variants, powering mRNA therapeutics for IPF (\$3B+ peak) within \$100B fibrosis/longevity market. Novel multicistronic approach achieved in vitro POC with superiority over SOC; advancing to IND. Backed by aMoon, Entrée, NfX, Tal and Alumni ventures. CEO-led team excels in mRNA drug development and preclinical validation.
- **Core Technology:** What is the technology, its uniqueness, and its value proposition? CaVos' proprietary platform integrates multi-level genomic algorithms with crossspecies data to identify antifibrotic/longevity "superpowers" overlooked by human screens. Uniqueness: Harnesses evolution for first-in-class mRNA payloads with superior efficacy/safety. Value: Scalable LNP therapeutics targeting IPF/multi-organ fibrosis (\$100B+ market), enabling precise pathway modulation and healthspan extension.
- **Product Profile/Pipeline:** Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships. Proprietary mRNA-LNP candidates recapitulate antifibrotic variants from long-lived species. In vitro POC achieved in lung epithelial and fibroblasts cells (fibrosis suppression); advancing to nebulized IPF preclinical. Targets \$3B+ IPF/\$100B+ fibrosis markets. Milestones: In vivo POC, precision-cut slices, IND-enabling studies.
- **Business Strategy:** Briefly describe how the company will apply its core technology, generate short-term and long-term revenues.
- **What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans R&D & Preclinical/Clinical Plans:** Advancing lead mRNA-LNP candidates through IND-enabling studies in 2027, including nebulized delivery efficacy in IPF animal models and safety profiling